{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohort+C",
    "query": {
      "intervention": "Cohort C"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1121,
    "total_pages": 113,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohort+C&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-12T17:46:48.401Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05724121",
      "title": "Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Lymphocytic Leukemia (CLL)",
        "Waldenstr(SqrRoot)(Delta)m s Macroglobulinemia",
        "Mantle Cell Lymphoma",
        "Sudden Cardiac Death",
        "Cardiac Arrhythmias",
        "Hematologic Malignancies"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "110 Years",
        "sex": "ALL",
        "summary": "18 Years to 110 Years"
      },
      "enrollment_count": 135,
      "start_date": "2023-03-01",
      "completion_date": "2027-04-08",
      "has_results": false,
      "last_update_posted_date": "2026-08-07",
      "last_synced_at": "2026-09-12T17:46:48.401Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05724121"
    },
    {
      "nct_id": "NCT01967940",
      "title": "Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV",
        "HIV Infections",
        "Acquired Immunodeficiency Syndrome"
      ],
      "interventions": [
        {
          "name": "TAF",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "E/C/F/TAF",
          "type": "DRUG"
        },
        {
          "name": "Current failing ARV regimen",
          "type": "DRUG"
        },
        {
          "name": "ATV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2013-10-25",
      "completion_date": "2017-07-31",
      "has_results": true,
      "last_update_posted_date": "2018-11-16",
      "last_synced_at": "2026-09-12T17:46:48.401Z",
      "location_count": 5,
      "location_summary": "Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more",
      "locations": [
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Wilton Manors",
          "state": "Florida"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01967940"
    },
    {
      "nct_id": "NCT04041310",
      "title": "Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "GAd-209-FSP low dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA-209-FSP low dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GAd-209-FSP high dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA-209-FSP high dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GAd20-209-FSP, RP2D",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA-209-FSP, RP2D",
          "type": "BIOLOGICAL"
        },
        {
          "name": "KEYTRUDA®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Nouscom SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 115,
      "start_date": "2019-10-21",
      "completion_date": "2026-10-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-09-12T17:46:48.401Z",
      "location_count": 13,
      "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 9 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Miami Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04041310"
    },
    {
      "nct_id": "NCT07728838",
      "title": "Contralateral Blood Flow Resistance Improves Scapular Muscle Activation During Pickleball Forehand Swings",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Shoulder and Upper Arm Injury"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Texas Woman's University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "18 Years to 30 Years"
      },
      "enrollment_count": 30,
      "start_date": "2024-05-01",
      "completion_date": "2025-11-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-27",
      "last_synced_at": "2026-09-12T17:46:48.401Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07728838"
    },
    {
      "nct_id": "NCT04140526",
      "title": "Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Advanced Solid Tumor",
        "Metastatic Melanoma",
        "Metastatic Head and Neck Carcinoma",
        "Metastatic Renal Cell Carcinoma",
        "Metastatic Colorectal Cancer",
        "Sarcomas",
        "Metastatic Prostate Cancer",
        "Ovarian Cancer",
        "Small Cell Lung Cancer",
        "Metastatic Breast Cancer",
        "Pancreas Cancer",
        "Gastric Cancer",
        "Esophageal Cancer",
        "Gastroesophageal Junction Adenocarcinoma",
        "Cervical Cancer",
        "Adenoid Cystic Carcinoma",
        "Salivary Gland Cancer",
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "ONC-392",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OncoC4, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 733,
      "start_date": "2020-09-16",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-05-23",
      "last_synced_at": "2026-09-12T17:46:48.401Z",
      "location_count": 33,
      "location_summary": "Springdale, Arkansas • Davis, California • Downey, California + 27 more",
      "locations": [
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04140526"
    },
    {
      "nct_id": "NCT00047047",
      "title": "Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "tanespimycin",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2002-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-06-04",
      "last_synced_at": "2026-09-12T17:46:48.401Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00047047"
    },
    {
      "nct_id": "NCT02946047",
      "title": "The Effect of Ixazomib on the Latent HIV Reservoir",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Human Immunodeficiency Virus (HIV)"
      ],
      "interventions": [
        {
          "name": "Ixazomib 1 MG",
          "type": "DRUG"
        },
        {
          "name": "Ixazomib 2 MG",
          "type": "DRUG"
        },
        {
          "name": "Ixazomib 3 MG",
          "type": "DRUG"
        },
        {
          "name": "Ixazomib 4 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2017-03-20",
      "completion_date": "2019-08-19",
      "has_results": true,
      "last_update_posted_date": "2022-01-06",
      "last_synced_at": "2026-09-12T17:46:48.401Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02946047"
    },
    {
      "nct_id": "NCT05822245",
      "title": "A Study of PER-001 in Participants With Open-Angle Glaucoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Open-angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "PER-001 Intravitreal Implant - Low Dose",
          "type": "DRUG"
        },
        {
          "name": "PER-001 Intravitreal Implant - High Dose",
          "type": "DRUG"
        },
        {
          "name": "PER-001 Intravitreal Implant - Sham",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Perfuse Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2023-05-25",
      "completion_date": "2025-04-20",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-09-12T17:46:48.401Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05822245"
    },
    {
      "nct_id": "NCT01610388",
      "title": "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infections, Bacterial"
      ],
      "interventions": [
        {
          "name": "500mg IV GSK1322322/placebo",
          "type": "DRUG"
        },
        {
          "name": "1000mg oral GSK1322322/placebo",
          "type": "DRUG"
        },
        {
          "name": "1000mg IV GSK1322322/placebo",
          "type": "DRUG"
        },
        {
          "name": "1500mg oral GSK1322322/placebo dose",
          "type": "DRUG"
        },
        {
          "name": "1500mg IV GSK1322322/placebo",
          "type": "DRUG"
        },
        {
          "name": "2000mg IV GSK1322322J/placebo",
          "type": "DRUG"
        },
        {
          "name": "3000mg IV GSK1322322J/placebo",
          "type": "DRUG"
        },
        {
          "name": "1000mg IV GSK1322322J/placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 61,
      "start_date": "2011-09-13",
      "completion_date": "2012-01-26",
      "has_results": false,
      "last_update_posted_date": "2017-06-12",
      "last_synced_at": "2026-09-12T17:46:48.401Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01610388"
    },
    {
      "nct_id": "NCT01133405",
      "title": "A Safety Study of LY2886721 Single Doses in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "LY2886721",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "20 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2010-06",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2019-09-16",
      "last_synced_at": "2026-09-12T17:46:48.401Z",
      "location_count": 1,
      "location_summary": "Beverly Hills, California",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01133405"
    }
  ]
}